Halozyme Therapeutics, Inc.
HALO
$107.39
-$0.92-0.85%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 47.67% | 42.23% | 51.60% | 22.12% | 40.79% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 47.67% | 42.23% | 51.60% | 22.12% | 40.79% |
| Cost of Revenue | 67.19% | 65.81% | 77.08% | 6.79% | 5.37% |
| Gross Profit | 42.91% | 34.84% | 44.83% | 26.81% | 53.37% |
| SG&A Expenses | 36.97% | 36.63% | 49.89% | 11.75% | 16.53% |
| Depreciation & Amortization | 66.15% | 66.15% | 31.61% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.84% | 55.84% | 61.11% | 7.45% | 8.03% |
| Operating Income | 42.09% | 30.37% | 44.95% | 33.53% | 72.68% |
| Income Before Tax | 39.02% | 25.38% | -156.59% | 32.58% | 74.06% |
| Income Tax Expenses | 38.24% | 17.66% | -1.12% | 55.43% | 62.37% |
| Earnings from Continuing Operations | 39.21% | 27.06% | -203.34% | 27.89% | 77.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 39.21% | 27.06% | -203.34% | 27.89% | 77.12% |
| EBIT | 42.09% | 30.37% | 44.95% | 33.53% | 72.68% |
| EBITDA | 44.11% | 34.37% | 43.47% | 30.02% | 62.75% |
| EPS Basic | 44.04% | 32.52% | -211.02% | 38.40% | 85.56% |
| Normalized Basic EPS | 43.84% | 32.31% | 53.71% | 43.48% | 82.35% |
| EPS Diluted | 42.86% | 31.18% | -213.33% | 36.19% | 84.72% |
| Normalized Diluted EPS | 42.40% | 30.75% | 56.83% | 41.04% | 81.14% |
| Average Basic Shares Outstanding | -3.35% | -4.12% | -6.91% | -7.59% | -4.54% |
| Average Diluted Shares Outstanding | -2.37% | -2.98% | -8.77% | -6.00% | -3.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |